| Document |
Document Title |
|
WO/2024/086790A1 |
The present disclosure provides 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine compounds of formula (I), which are therapeutically useful as USP1 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or...
|
|
WO/2024/084491A1 |
The present invention discloses a process for synthesis of Res metirom and its intermediates thereof. More particularly, the invention discloses process for synthesis of a key intermediate, 6-(4-amino, 2,6-dichlorophenoxy)4- isopropylpyr...
|
|
WO/2024/086569A1 |
N-Biarylmethylene substituted pyrrolopyridinone, pyrrolopyrazinone, pyrrolopyrimidinone, and isoindolin-1-one compounds having a primary or secondary alcohol-containing group substituted on the biarylmethylene are positive allosteric mod...
|
|
WO/2024/083220A1 |
A ligand-oligonucleotide conjugate and a linker for the conjugate, the linker including the structure of formula I or II: -NR1-C(O)-[C(R3R4)]n-C(O)-[NR2-C(RaRb)-C(O)]p- (formula I), or -NR1-[C(O)-C(RaRb)-NR2]p-C(O)-[C(R3R4)]n-C(O)- (form...
|
|
WO/2024/082724A1 |
It relates to the combination of PIM kinase inhibitor and a KRAS inhibitor for use in treating cancer, in a subject in need thereof. Also provided are compositions or kits comprising same. Furthermore, it also relates to a PIM kinase inh...
|
|
WO/2024/086619A2 |
The present disclosure provides for a nucleic acids encoding for a transforming growth factor inhibitor and IL-12. Further provided herein are nucleic acids encoding for chemokine receptor CXCR3. Additionally described herein are oncolyt...
|
|
WO/2024/083120A1 |
Disclosed in the present invention are a benzylaminoquinoline compound and a preparation method therefor. The present invention specifically relates to a compound represented by formula (II), a stereoisomer thereof and a pharmaceutically...
|
|
WO/2024/086535A2 |
The present application provides compounds and methods for iron replacement therapy.
|
|
WO/2024/083230A1 |
It relates to novel formulations of epinephrine that comprise polyoxymethylene alkyl ethers as a permeation enhancer, methods of administering the formulation, and uses thereof.
|
|
WO/2024/054785A3 |
Provided herein is a method for determining selectively increasing the expression levels of SSTR5 in pituitary tumor cells in a patient, the method comprising administering to the patient a glucocorticoid receptor modulator (GRM) to the ...
|
|
WO/2024/082638A1 |
Provided in the present invention is the use of dimetridazole in the preparation of a drug for treating feline diarrhea caused by Tritrichomonas foetus in cats, and also provided is a dimetridazole chewable tablet preparation.
|
|
WO/2024/086317A1 |
The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cognitive impairment.
|
|
WO/2024/082408A1 |
The present invention relates to a use of a JWA polypeptide in the preparation of an anti-tumor drug co-potentiator. The amino acid sequence of the polypeptide is as shown in I or II: I: FPGSDRF-Z, and II: X-FPGSDRF-Z, the amino acid S b...
|
|
WO/2024/085100A1 |
The present disclosure relates to a solid particle dispersed oily preparation. The present disclosure also provides a solid particle dispersed oily preparation suited to eyedrops or intraocular administration. The solid particle disperse...
|
|
WO/2024/083117A1 |
The present invention provides a drug combination comprising Nafamostat and K777 and a use thereof. The pharmaceutical composition comprises active ingredients, i.e., Nafamostat and K777. The pharmaceutical composition of the present inv...
|
|
WO/2024/085149A1 |
The present invention addresses the problem of providing a capsule particle manufacturing method. Provided is a method for manufacturing capsule particles by using a Taylor reactor.
|
|
WO/2024/082654A1 |
Compounds having poly ADP-ribose polymerase inhibitory activity, pharmaceutical compositions thereof, and uses thereof are disclosed. In particular, the present invention relates to compounds of formula (I), pharmaceutical compositions c...
|
|
WO/2024/084447A2 |
Compounds of formula (I) and an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3 and W, are as defined in the specification, are usef...
|
|
WO/2024/086713A1 |
The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.
|
|
WO/2024/084290A1 |
It is an object of he present invention a composition and a formulation containing said composition and, optionally, additives or excipients or carriers of acceptable food or pharmaceutical grade. Further, the present invention relates t...
|
|
WO/2024/082696A1 |
The present invention relates to the field of medicine, and specifically relates to a use of a small molecule compound and lenalidomide in the preparation of a drug for the treatment of multiple myeloma. How to promote the degradation of...
|
|
WO/2024/036094A3 |
Methods for facilitating the genesis of photoreceptor rods in a subject by administering a therapeutically effective amount of a therapeutic agent are provided. Other methods are provided for treating retinitis pigmentosa by administerin...
|
|
WO/2024/086331A1 |
The present disclosure provides biochemically responsive Fe(II) and Fe(III) complexes useful as magnetic resonance imaging probes for diagnosis and monitoring acute and chronic inflammatory diseases affecting various organs and tissues.
|
|
WO/2024/031058A3 |
Disclosed is a method of treating a subject who has a neurological disease. The neurological disease may be associated with altered FOXG1 expression. In one aspect, the method includes a step of administering an effective dose of a FOXG1...
|
|
WO/2024/085695A1 |
The present invention relates to a novel altiratinib derivative, a manufacturing method therefor, and a composition comprising same as an active ingredient for the prevention, alleviation, or treatment of skin pigmentation. The altiratin...
|
|
WO/2024/006726A3 |
Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a d...
|
|
WO/2024/084496A1 |
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib maleate and one or more pharmace...
|
|
WO/2024/083086A1 |
A bicyclic αvβ1, αvβ6 and αvβ8 integrin inhibitor compound represented by formula (I), and a racemate, stereoisomer, tautomer, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, and a pharma...
|
|
WO/2024/083257A1 |
Provided in the present invention are an SOS1 protein degradation agent and a use thereof. Specifically, provided in the present invention is a formula (I) for a S-L-E compound, and a stereoisomer, enantiomer, diastereomer, deuterated co...
|
|
WO/2024/084785A1 |
The purpose of the present invention is to provide a composition having higher efficacy and safety and suitable for use as a RS virus vaccine. Provided is a composition containing G protein and a CpG oligodeoxynucleotide of a RS virus,...
|
|
WO/2024/084428A1 |
The present invention relates to a composition of substances effective in the prevention and/or treatment of cardiovascular system diseases, respiratory system diseases, immune system diseases, reproductive system diseases, nervous syste...
|
|
WO/2024/083182A1 |
The present invention relates to a method for preparing a phosphonyl derivative, and specifically relates to a method for preparing the compound as represented by formula (A) and intermediates thereof. The method is mild in reaction cond...
|
|
WO/2024/086268A1 |
The present invention provides a formulation that includes a therapeutically effective amount of phenylephrine or a pharmaceutically acceptable salt thereof, and a method for preparing the formulation. In some embodiments, the formulatio...
|
|
WO/2024/083024A1 |
Disclosed in the present invention are preparation and a use of a c-RET inhibitor. Specifically, the present invention provides a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical com...
|
|
WO/2024/084516A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure...
|
|
WO/2024/086352A2 |
Among other things, the present disclosure provides compositions, e.g., isolated nucleic acids, vectors, and recombinant adeno-associated viruses (rAAVs), comprising a nucleic acid sequence encoding a PRPF31 polypeptide. In some embodime...
|
|
WO/2024/086699A1 |
The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare stable therapeutic formulations, particularly sustained release formulations, of a variety of active pharmaceutical i...
|
|
WO/2024/086718A1 |
Lyophilized formulations comprising a compound of Formula (I) and one or more amino acids are provided, wherein W, X, Y, Z, Ra, Rc, and each Rg are as defined herein. Also provided are methods of preparation, methods of use, and dosage f...
|
|
WO/2024/082917A1 |
Disclosed are a crystal form A of bupivacaine-meloxicam salt, a single crystal thereof, a preparation method therefor and a use thereof. An X-ray powder diffraction pattern of the crystal form A of the bupivacaine-meloxicam salt has char...
|
|
WO/2024/082959A1 |
The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. This fluorescent compound is then encapsulated by polymer matrix to yield nanoaggregates which is confirmed to show an ...
|
|
WO/2024/084394A1 |
Compounds and methods are provided for facilitating delivery of an oligonucleotide, for example, into a nucleus and/or cytosol of a cell.
|
|
WO/2024/084520A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop str...
|
|
WO/2024/083256A1 |
Provided in the present invention are a pan-KRAS degrading agent, and a preparation method therefor and the use thereof. Specifically, disclosed in the present invention are a small molecule compound for targeted degradation of the pan-K...
|
|
WO/2024/083980A1 |
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
|
WO/2024/085603A1 |
The present invention relates to a pharmaceutical composition for preventing or treating c-Myc-associated diseases, and use thereof, the composition comprising a preparation that inhibits the expression or activity of ubiquitin-specific ...
|
|
WO/2024/085417A1 |
The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata by acting as a functional inhibitor against S1P receptor subtypes S1PR1 and S1PR4, and, more particularly, to a pharmaceutical compo...
|
|
WO/2024/085170A1 |
The purpose of the prevent invention is to develop and provide a drug for alleviating, resolving, remitting or treating a symptom of a patient who develops aftereffects of a viral infection. A tricyclic compound represented by general ...
|
|
WO/2024/085053A1 |
Provided is a composition that can form a powder having few aggregates, can form a powder having exceptional properties for re-dispersion in an aqueous medium, and moreover can form a powder having exceptional properties for re-dispersio...
|
|
WO/2024/086194A1 |
The present disclosure describes methods of treating a subject suffering from cancer using a combination therapy comprising (i) administering to the subject a therapeutically-effective amount of a compound that blocks SUMOylation in the ...
|
|
WO/2023/055939A9 |
The disclosed apparatus, systems and methods relate to a permeation enhancing transdermal patch for the administration of a therapeutic compound transdermally. A transdermal patch for the administration of a therapeutic compound to a sub...
|
